The Craneware Group convened leaders from 25 major U.S. health systems, alongside representatives from Beacon/ESP (Berkeley Research Group) and Apexus, the HRSA 340B Prime Vendor, at its U.S.

Johnson & Johnson has decided to terminate implementation of its 340B rebate plan, according to an internal email 340B Health shared with Becker’s. In late August, the drugmaker planned to replace ...

July 11, 2023 - The federal 340B Drug Pricing Program ("340B"), which is intended to help safety-net health care providers stretch their financial resources to reach more financially vulnerable ...

Here we go again: An op-ed column printed in this publication is yet another example of a drug company-focused view on the 340B Drug Pricing Program, couched in the language of reform. Its criticisms ...

If HHS’ 340B rebate model pilot proceeds as planned, more than 2,700 U.S. hospitals will collectively be saddled with approximately $400 million in operational costs and 11.2 million labor burden ...

The rapid expansion of the federal 340B drug pricing program is significantly affecting Medicaid budgets, particularly in states where managed care plans oversee prescription drug benefits. New ...

Recent court rulings have thrust the 340B Drug Pricing Program back in the headlines, and it is worth examining some of the lesser-known aspects of how this program interacts with state and federal ...

On April 28, AEI’s Kirsten Axelsen hosted the former North Carolina Department of Health and Human Services Secretary Kody Kinsley; Anthony DiGiorgio of the University of California, San Francisco; ...

The 340B program, which was created more than 30 years ago, allows healthcare providers that serve large populations of low-income patients to buy outpatient drugs at a significantly discounted rate.

The drugmaker has joined Johnson & Johnson and Eli Lilly in filing suit against the Biden administration over controversial reform to the drug discount program. The 340B program was created more than ...